NervGen Pharma Corp.
NGENF
$4.48
$0.255.91%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.25M | 2.72M | 2.01M | 1.58M | 2.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.48M | 4.68M | 4.21M | 4.86M | 5.30M |
| Operating Income | -4.48M | -4.68M | -4.21M | -4.86M | -5.30M |
| Income Before Tax | -3.02M | -6.58M | -2.75M | -6.15M | -3.88M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.02M | -6.58M | -2.75M | -6.15M | -3.88M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.02M | -6.58M | -2.75M | -6.15M | -3.88M |
| EBIT | -4.48M | -4.68M | -4.21M | -4.86M | -5.30M |
| EBITDA | -4.47M | -4.67M | -4.20M | -4.85M | -5.29M |
| EPS Basic | -0.04 | -0.09 | -0.04 | -0.09 | -0.06 |
| Normalized Basic EPS | -0.03 | -0.06 | -0.02 | -0.05 | -0.03 |
| EPS Diluted | -0.04 | -0.09 | -0.04 | -0.09 | -0.06 |
| Normalized Diluted EPS | -0.03 | -0.06 | -0.02 | -0.05 | -0.03 |
| Average Basic Shares Outstanding | 73.16M | 71.96M | 70.67M | 69.99M | 70.07M |
| Average Diluted Shares Outstanding | 73.16M | 71.96M | 70.67M | 69.99M | 70.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |